<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755442</url>
  </required_header>
  <id_info>
    <org_study_id>20120189</org_study_id>
    <nct_id>NCT01755442</nct_id>
  </id_info>
  <brief_title>Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure &amp; Glucose Levels in Type 2 Diabetes Mellitus Subjects</brief_title>
  <official_title>A Phase 1, Double-blind, Randomized, 2-Way Crossover, Placebo-controlled Study to Investigate the Effect of AMG 151 on 24-hour Ambulatory Blood Pressure and Glucose Levels in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized, double-blind, placebo-controlled, 2-way crossover study to&#xD;
      evaluate the effect of AMG 151 on 24-hour ambulatory blood pressure and glucose levels in&#xD;
      subjects with type 2 diabetes mellitus who are on a stable regimen of metformin alone,&#xD;
      metformin and a dipeptidyl peptidase-4 inhibitor (DPP4), metformin and a thiazolidinedione&#xD;
      (TZD), or metformin, a DPP4, and a TZD for a minimum of 3 months prior to randomization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Amgen determined no further need for this study.&#xD;
  </why_stopped>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean 24-hour systolic blood pressure</measure>
    <time_frame>After 14 days of AMG 151 or placebo treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean 24-hour diastolic blood pressure</measure>
    <time_frame>After 14 days of AMG 151 or placebo treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean 24-hour heart rate</measure>
    <time_frame>After 14 days of AMG 151 or placebo treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour concentration time profile of glucose level from continuous glucose monitoring</measure>
    <time_frame>Day 1 and day 14 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose and fructosamine</measure>
    <time_frame>After 13 days of AMG 151 or placebo treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose 2 hours after time 0 of mixed meal tolerance test</measure>
    <time_frame>After 13 days of AMG 151 or placebo treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-hour concentration time profile of glucose after the mixed meal tolerance test</measure>
    <time_frame>After 13 days of AMG 151 or placebo treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety end points will include the incidence of treatment emergent adverse events.</measure>
    <time_frame>Up to 2 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum AMG 151 concentration</measure>
    <time_frame>Up to 2 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety end points will include laboratory safety tests.</measure>
    <time_frame>Up to 2 Months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety end points will include vital signs.</measure>
    <time_frame>Up to 2 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety end points will include ECGs.</measure>
    <time_frame>Up to 2 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>AMG 151</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 151</intervention_name>
    <description>Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.</description>
    <arm_group_label>AMG 151</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Subjects with type 2 diabetes mellitus&#xD;
&#xD;
          -  On a stable regimen of metformin alone, metformin and a DPP4, metformin and a TZD, or&#xD;
             metformin, a DPP4, and a TZD for a minimum of 3 months prior to randomization&#xD;
&#xD;
          -  Body mass indices &gt; 25 and &lt; 45 kg/m2&#xD;
&#xD;
          -  Hemoglobin A1c levels ≥ 7.0% and ≤ 11.0% at screening&#xD;
&#xD;
          -  Fasting C-peptide levels ≥ 0.2 nmol/L at screening&#xD;
&#xD;
          -  Subject with a history of hypertension must be on a stable antihypertensive treatment&#xD;
             (s) (type of medication, dose, and regimen) for at least 6 weeks prior to the first&#xD;
             dose of investigational product&#xD;
&#xD;
          -  Other criteria may apply&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Subject has type 1 diabetes mellitus or history of type 1 diabetes mellitus&#xD;
&#xD;
          -  Subject has had 2 or more emergency room visits or hospitalizations due to poor&#xD;
             glucose control in the 6 months prior to screening&#xD;
&#xD;
          -  Poorly controlled hypertension defined as diastolic pressure ≥ 95 mmHg or systolic ≥&#xD;
             155 mmHg (confirmed by a repeat assessment) at screening&#xD;
&#xD;
          -  Triglycerides ≥ 400 mg/dL (4.52 mmol/L) at screening&#xD;
&#xD;
          -  Use of any known cytochrome P450 (CYP) inducers within 30 days or 5 half-lives&#xD;
             (whichever is longer), prior to receiving the first dose of investigational product.&#xD;
&#xD;
          -  Use of any known inhibitors of CYP3A4/P-glycoprotein within the 14 days or 5 half&#xD;
             lives (whichever is longer) prior to receiving the first dose of investigational&#xD;
             product&#xD;
&#xD;
          -  Other criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>November 27, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <last_update_submitted>April 19, 2013</last_update_submitted>
  <last_update_submitted_qc>April 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ambulatory blood pressure</keyword>
  <keyword>Type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

